Sphingosomal vincristine plus rituximab for treatment of large B-cell lymphoma.

被引：0
|
作者：
Ashcroft, AJ
Kaplan, LD
Damon, LE
Morgan, GJ
机构：
[1] Univ Leeds, Acad Unit Haematol & Oncol, Leeds, W Yorkshire, England
[2] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1454
引用
收藏
页码：400A / 401A
页数：2
相关论文
共 50 条
  • [21] Efficiency of rituximab plus DRAP in the treatment of patients with mantle cell lymphoma.
    Jaccard, A
    Touati, M
    Gachard, N
    Chaury, MP
    Remenieras, L
    Turlure, P
    Bordessoule, D
    BLOOD, 2002, 100 (11) : 315B - 315B
  • [22] Liposomal doxorubicin-liposomal doxorubicin-rituximab for the treatment of elderly patients with diffuse large B-cell lymphoma.
    Zaja, F
    Tomadini, V
    Zaccaria, A
    Lauria, F
    Molinari, AL
    Fabbri, A
    Battista, R
    Angelucci, E
    Gallamini, A
    Battista, M
    Fanin, R
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 606S - 606S
  • [23] Treatment of follicular Lymphoma B-cell with rituximab
    Petryk, Gwen
    CANADIAN PHARMACISTS JOURNAL, 2010, 143 : S5 - +
  • [24] Unusual presentation of diffuse large B-cell lymphoma.
    Persing, B.
    Herrin, V.
    Elkins, S.
    Files, J.
    Bigelow, C.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2007, 55 (01) : S268 - S268
  • [25] Expression of mTOR in diffuse large B-cell lymphoma.
    Gopaluni, Srivalli
    Vajpayee, Neerja
    Newman, Nancy
    Thakral, Charu
    Husain, Juhi
    Gajra, Ajeet
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [26] Novel combination of gallium nitrate, rituximab and dexamethasone for the treatment of relapsed or refractory diffuse large B-cell lymphoma, mantle cell lymphoma or transformed follicular lymphoma.
    Smith, SE
    Stiff, PJ
    Rodriguez, T
    Toor, A
    Klein, J
    BLOOD, 2005, 106 (11) : 269B - 269B
  • [27] Rituximab is an effective treatment in cutaneous histiocyte predominant T-cell rich B-cell lymphoma.
    Hopkins, TV
    Floyd, J
    Loy, T
    Johnston, N
    Shahab, N
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 619S - 619S
  • [28] Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
    Younes, Anas
    Sehn, Laurie H.
    Johnson, Peter
    Zinzani, Pier Luigi
    Hong, Xiaonan
    Zhu, Jun
    Patti, Caterina
    Belada, David
    Samoilova, Olga
    Suh, Cheolwon
    Leppae, Sirpa
    Rai, Shinya
    Turgut, Mehmet
    Jurczak, Wojciech
    Cheung, Matthew C.
    Gurion, Ronit
    Yeh, Su-Peng
    Lopez-Hernandez, Andres
    Duehrsen, Ulrich
    Thieblemont, Catherine
    Chiattone, Carlos Sergio
    Balasubramanian, Sriram
    Carey, Jodi
    Liu, Grace
    Shreeve, S. Martin
    Sun, Steven
    Zhuang, Sen Hong
    Vermeulen, Jessica
    Staudt, Louis M.
    Wilson, Wyndham
    Fisher, Richard I.
    Engert, Andreas
    Stadtmauer, Edward A.
    Wei, Lee-Jen
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15) : 1285 - +
  • [29] Rituximab and chemotherapy in diffuse large B-cell lymphoma
    Sonet, Anne
    Bosly, Andre
    EXPERT REVIEW OF ANTICANCER THERAPY, 2009, 9 (06) : 719 - 726
  • [30] Role of Rituximab and Rituximab Biosimilars in Diffuse Large B-Cell Lymphoma
    Coleman, Morton
    Lammers, Philip E.
    Ciceri, Fabio
    Jacobs, Ira A.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (04): : 175 - 181
12345